BOULDER — Think Bioscience Inc. recently raised an oversubscribed $55 million Series A round. Think Bioscience Inc. recently raised an oversubscribed $55 million Series A round.

We are grateful for the collaborative feedback from FDA on the Gemini program, which provides us a clear and expedient path forward for seeking approval of Gemini as a treatment for AKI,” said, James ...

Presentation to Include Additional Positive Data from the Recently Completed PRIME Clinical Study - SAN DIEGO, CA / ...

SAN DIEGO, CA / ACCESS Newswire / January 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or ...

Jade Biosciences Inc. (NASDAQ:JBIO) is one of the overlooked growth stocks to buy. On January 7, H.C. Wainwright initiated coverage of Jade Biosciences with a Buy rating and $25 price target. The firm ...

In September 2025, the Company launched AboutNAD®, a next-generation digital platform designed to serve as the leading online resource for scientific advancements in NAD+ research and healthy aging.

Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026; SGT-003 continues to be ...

Holliston biotechnology firm Harvard Bioscience continued its fourth quarter momentum with revenue up 14% in the first quarter of 2021 when compared to the first quarter of 2020. Holliston ...

“We delivered an excellent second quarter, with $31.1 million in net sales, up 37% year-over-year, and $3.6 million in net income,” said Niagen Bioscience CEO Rob Fried. “As the pioneers of this ...